开云app官网登录入口网页版-官方正版

#2期临床#

38篇内容 | 1344人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1970277, encodeId=f43d19e0277f1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点, objectType=article, longId=728899, objectId=ab8ce28899e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab8ce28899e0, replyNumber=0, likeNumber=99, createdTime=2022-12-08, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab8ce28899e0, moduleTitle=结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ab8ce28899e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970279, encodeId=142119e027936, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=关于羟氯喹的2期临床试验解读, objectType=article, longId=732997, objectId=09eee3299776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09eee3299776, replyNumber=0, likeNumber=94, createdTime=2022-12-20, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09eee3299776, moduleTitle=关于羟氯喹的2期临床试验解读, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=09eee3299776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970278, encodeId=8f4819e027892, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=NEJM发布遗传性肝病RNAi疗法2期临床试验结果，降低致病蛋白83%, objectType=article, longId=730942, objectId=b578e309426a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b578e309426a, replyNumber=0, likeNumber=100, createdTime=2022-11-27, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b578e309426a, moduleTitle=NEJM发布遗传性肝病RNAi疗法2期临床试验结果，降低致病蛋白83%, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b578e309426a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970276, encodeId=bc8719e02764e, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=重磅！BNT162b2 mRNA新冠疫苗复必泰2期临床试验结果发布, objectType=article, longId=728324, objectId=3580e2832448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3580e2832448, replyNumber=0, likeNumber=103, createdTime=2022-11-22, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3580e2832448, moduleTitle=重磅！BNT162b2 mRNA新冠疫苗复必泰2期临床试验结果发布, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3580e2832448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970280, encodeId=da0419e028038, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=阿尔兹海默症疫苗来了！2期临床试验安全性良好，且能诱导患者免疫应答, objectType=article, longId=291115, objectId=8c1229111571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c1229111571, replyNumber=0, likeNumber=68, createdTime=2022-03-12, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c1229111571, moduleTitle=阿尔兹海默症疫苗来了！2期临床试验安全性良好，且能诱导患者免疫应答, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8c1229111571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970275, encodeId=3a2c19e027562, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=83, createdTime=2021-08-08, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970273, encodeId=03a919e027390, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Clin Exp Rheumatol：2期临床试验结果证实尼塔奇单抗对活动性强直性脊柱炎良好的疗效和安全性, objectType=article, longId=210766, objectId=f03d210e6684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f03d210e6684, replyNumber=0, likeNumber=99, createdTime=2022-01-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f03d210e6684, moduleTitle=Clin Exp Rheumatol：2期临床试验结果证实尼塔奇单抗对活动性强直性脊柱炎良好的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f03d210e6684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Nat Aging：阿尔兹海默症疫苗来了！2期临床试验有效诱导免疫应答, objectType=article, longId=212766, objectId=b3bb212e6668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3bb212e6668, replyNumber=0, likeNumber=97, createdTime=2021-11-01, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3bb212e6668, moduleTitle=Nat Aging：阿尔兹海默症疫苗来了！2期临床试验有效诱导免疫应答, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b3bb212e6668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970272, encodeId=580419e027261, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=腾盛博药、Vir Biotechnology和VBI Vaccines宣布启动BRII-835 (VIR-2218)联合BRII-179 (VBI-2601)治疗乙型肝炎的2期临床试验, objectType=article, longId=210372, objectId=3bb22103e2fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bb22103e2fc, replyNumber=0, likeNumber=81, createdTime=2021-10-03, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bb22103e2fc, moduleTitle=腾盛博药、Vir Biotechnology和VBI Vaccines宣布启动BRII-835 (VIR-2218)联合BRII-179 (VBI-2601)治疗乙型肝炎的2期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3bb22103e2fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970271, encodeId=e83f19e027136, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效, objectType=article, longId=203466, objectId=48e120346625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48e120346625, replyNumber=0, likeNumber=78, createdTime=2021-08-20, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48e120346625, moduleTitle=非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=48e120346625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970270, encodeId=5ea419e027001, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代, objectType=article, longId=200929, objectId=978320092943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978320092943, replyNumber=0, likeNumber=117, createdTime=2020-12-26, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978320092943, moduleTitle=Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=978320092943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970268, encodeId=04b319e026851, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=加环利定耳内局部制剂OTO-313治疗耳鸣，1/2期临床获得更佳阳性结果, objectType=article, longId=197189, objectId=a47719e1893d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a47719e1893d, replyNumber=0, likeNumber=84, createdTime=2020-12-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a47719e1893d, moduleTitle=加环利定耳内局部制剂OTO-313治疗耳鸣，1/2期临床获得更佳阳性结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a47719e1893d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970269, encodeId=6fac19e026950, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=NEJM：新冠病毒疫苗NVX-CoV2373的1-2期临床试验结果, objectType=article, longId=200243, objectId=97ee20024318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97ee20024318, replyNumber=0, likeNumber=87, createdTime=2020-09-25, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97ee20024318, moduleTitle=NEJM：新冠病毒疫苗NVX-CoV2373的1-2期临床试验结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=97ee20024318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970267, encodeId=008119e0267eb, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效, objectType=article, longId=195471, objectId=2fd71954e152, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fd71954e152, replyNumber=0, likeNumber=129, createdTime=2020-11-14, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fd71954e152, moduleTitle=EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2fd71954e152)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970261, encodeId=645c19e0261e0, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Scancell的DNA肿瘤疫苗治疗黑色素瘤将开展2期临床试验, objectType=article, longId=174672, objectId=6b1c1e46728d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1c1e46728d, replyNumber=0, likeNumber=136, createdTime=2019-10-17, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1c1e46728d, moduleTitle=Scancell的DNA肿瘤疫苗治疗黑色素瘤将开展2期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6b1c1e46728d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970265, encodeId=680c19e026586, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=FDA批准了基于噬菌体治疗多药耐药感染的1/2期临床研究, objectType=article, longId=190011, objectId=468d19001160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d19001160, replyNumber=0, likeNumber=88, createdTime=2020-07-06, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d19001160, moduleTitle=FDA批准了基于噬菌体治疗多药耐药感染的1/2期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=468d19001160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970263, encodeId=5b4f19e026383, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Blood：2期临床试验：Concizumab可有效预防各型血友病患者出血, objectType=article, longId=178314, objectId=3d3e1e8314ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d3e1e8314ea, replyNumber=0, likeNumber=134, createdTime=2019-09-24, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d3e1e8314ea, moduleTitle=Blood：2期临床试验：Concizumab可有效预防各型血友病患者出血, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3d3e1e8314ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970266, encodeId=133e19e0266c9, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究, objectType=article, longId=193097, objectId=69fe19309e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69fe19309e48, replyNumber=0, likeNumber=118, createdTime=2021-03-15, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69fe19309e48, moduleTitle=Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=69fe19309e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970262, encodeId=761f19e0262ed, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=融资6000万美元，自体免疫疾病新药进入2期临床, objectType=article, longId=177750, objectId=ad9b1e775063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad9b1e775063, replyNumber=0, likeNumber=71, createdTime=2020-06-21, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad9b1e775063, moduleTitle=融资6000万美元，自体免疫疾病新药进入2期临床, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ad9b1e775063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970264, encodeId=071419e0264f2, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda，用于晚期非小细胞肺癌的2期临床达到终点, objectType=article, longId=182592, objectId=625c1825922c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625c1825922c, replyNumber=0, likeNumber=77, createdTime=2020-04-22, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625c1825922c, moduleTitle=酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda，用于晚期非小细胞肺癌的2期临床达到终点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=625c1825922c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

2期临床

2020-05-29

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点

2022-12-08

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

关于羟氯喹的2期临床试验解读

2022-12-20

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

NEJM发布遗传性肝病RNAi疗法2期临床试验结果，降低致病蛋白83%

2022-11-27

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

重磅！BNT162b2 mRNA新冠疫苗复必泰2期临床试验结果发布

2022-11-22

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

阿尔兹海默症疫苗来了！2期临床试验安全性良好，且能诱导患者免疫应答

2022-03-12

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-08-08

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Clin Exp Rheumatol：2期临床试验结果证实尼塔奇单抗对活动性强直性脊柱炎良好的疗效和安全性

2022-01-09

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Nat Aging：阿尔兹海默症疫苗来了！2期临床试验有效诱导免疫应答

2021-11-01

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

腾盛博药、Vir Biotechnology和VBI Vaccines宣布启动BRII-835 (VIR-2218)联合BRII-179 (VBI-2601)治疗乙型肝炎的2期临床试验

2021-10-03

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效

2021-08-20

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代

2020-12-26

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

加环利定耳内局部制剂OTO-313治疗耳鸣，1/2期临床获得更佳阳性结果

2020-12-05

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

NEJM：新冠病毒疫苗NVX-CoV2373的1-2期临床试验结果

2020-09-25

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效

2020-11-14

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Scancell的DNA肿瘤疫苗治疗黑色素瘤将开展2期临床试验

2019-10-17

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

FDA批准了基于噬菌体治疗多药耐药感染的1/2期临床研究

2020-07-06

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Blood：2期临床试验：Concizumab可有效预防各型血友病患者出血

2019-09-24

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究

2021-03-15

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

融资6000万美元，自体免疫疾病新药进入2期临床

2020-06-21

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda，用于晚期非小细胞肺癌的2期临床达到终点

2020-04-22

科室
- - 订阅+
  - 更多科室
工具
服务